Skip to main content

Table 2 Comparison of primary endpoints and key secondary endpoints (ITT population)

From: Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)

 

SD-101 6%

n = 82

Vehicle

n = 87

Nominal

P value

Primary endpoints

 Time to complete target wound closure within 3 months, mean (SD), day

(n = 39) 41.6 (25.5)

(n = 45) 53.6 (28.6)

0.985

 Complete closure of target wound within 3 months, response rate

(n = 79) 49.4%

(n = 84) 53.6%

0.390

Secondary endpoints

 Complete closure of target wound within 2 months, response rate

(n = 79) 43.0%

(n = 84) 42.9%

0.802

 Complete closure of target wound within 1 month, response rate

(n = 79) 31.6%

(n = 84) 22.6%

0.212

 Change in BSAi of lesional skin at Month 3, %

(n = 75)

(n = 78)

 

  Mean (SEM)

−4.4 (1.05)

−5.0 (1.53)

0.706

  Median (range)

−2.7 (− 37.4, 18.0)

−3.0 (− 69.2, 26.5)

 

 Change in BSAi of total body wound burden at Month 3, %

(n = 75)

(n = 79)

 

  Mean (SEM)

−3.5 (0.94)

−2.3 (0.70)

0.900

  Median (range)

−1.5 (−42.6, 12.5)

−1.4 (−24.1, 17.0)

 

 Change in itching score at Day 7

(n = 77)

(n = 79)

 

  Mean (SEM)

−0.5 (0.15)

−0.3 (0.14)

0.262

  Median (range)

0.0 (−4, 2)

0.0 (− 4, 3)

 

 Change in pain score at Day 7

(n = 77)

(n = 80)

 

 Mean (SEM)

−0.3 (0.29)

−0.6 (0.34)

0.098

 Median (range)

0.0 (−6, 10)

0.0 (−8, 10)

 
  1. BSAi body surface area index; ITT intent-to-treat; SEM standard error of the mean